
Cleveland Clinic Abu Dhabi saves vision for patient with rare invasive fungal sinusitis using advanced skull-base surgery
Cleveland Clinic Abu Dhabi's multidisciplinary approach and cutting-edge therapies enabled successful treatment of a rare invasive fungal sinusitis.
Abu Dhabi, United Arab Emirates: Cleveland Clinic Abu Dhabi, part of the M42 group, successfully saved a 57-year-old woman's eye from a rare and invasive fungal sinusitis through an extensive skull base surgery, preventing the need for orbital exenteration (eye removal).
The patient had previously undergone bilateral sinus surgery at a different hospital, which led to post-operative maxillary sinusitis - a condition where the sinuses behind the cheeks became infected or inflamed after the procedure. She was later admitted to the Emergency Department of Cleveland Clinic Abu Dhabi with severe right-sided facial pain and swelling. Despite initial treatment with antibiotics and steroids, her condition deteriorated, leading to nasal congestion, changes in her sense of smell, and debilitating headaches.
Further investigation, including an MRI, revealed mucosal thickening and a breakthrough in the thin bone separating her sinuses and orbital cavity, which caused the infection to get dangerously close to her eye and potentially spread further. A swab of the affected area confirmed an invasive fungal infection caused by Aspergillus; an infection caused by a type of fungus. If left untreated, the infection would have invaded deeper tissues of the orbit and possibly spread to nearby structures such as the brain, posing a significant threat to her life.
A multidisciplinary team led by Dr. Mahdi Shkoukani, Department Chair for Otolaryngology Head & Neck Surgery in the Surgical Subspecialties Institute at Cleveland Clinic Abu Dhabi, quickly recognized the urgency of the patient's condition. They performed an extensive surgical debridement to remove the infected tissue, including parts of the sinuses, the medial orbital wall, and the orbital fat around the eye.
Explaining the complex nature of the condition, Dr. Mahdi Shkoukani said: 'This was one of the rarest cases of sinusitis we encountered in recent years. Despite the patient being healthy and having a functioning immune system, the patient's fungal infection had progressed to a point where it posed a serious threat to her eye and brain if left untreated. The case underscores the importance of early diagnosis and rapid surgical and medical intervention for invasive fungal sinusitis. Through a complex and meticulous surgical procedure, we successfully removed all the infected tissue while preserving her vision. The multidisciplinary teamwork at Cleveland Clinic Abu Dhabi played a crucial role in achieving this positive outcome. We hope this story raises awareness about the severity of such infections and the importance of seeking immediate medical attention when symptoms persist or worsen.'
Following surgery, the patient's infection subsided, and her tissues began to heal. A second procedure two days later confirmed no further fungal invasion, sparing her from orbital exenteration. She was started on antifungal medications from day one when we first suspected the infection and was closely managed by the infectious disease team. Today, her sinuses have healed and her vision remains intact.
Dr. Shkoukani commented further: 'Fungi are typically harmless and naturally present in the sinuses. However, in certain conditions, they can become aggressive, spreading to surrounding tissues, including the eyes and brain. In patients with compromised immune systems, this invasion can progress rapidly, leading to a condition known as acute invasive fungal sinusitis. In immune-competent individuals, like our patient, the progression is usually slower, resulting in chronic invasive sinusitis. At Cleveland Clinic Abu Dhabi, our advanced facilities and multidisciplinary expertise enable us to manage such complex cases with precision and care.'
Reflecting on her journey, the patient shared: 'I'm incredibly grateful to the team at Cleveland Clinic Abu Dhabi for their swift action and expertise. It was a terrifying experience to think I might lose my eye, but their dedication and skill saved me. I never imagined something like a sinus infection could become so dangerous, and I hope my story encourages others to seek help early if they have persistent symptoms.'
This case, out of many, underscores Cleveland Clinic Abu Dhabi's expertise in complex care and its commitment to innovation and patient-centered care. The hospital continues to make a transformative impact in the lives of patients with world-class care. The hospital's Integrated Surgical Institute combines cutting-edge diagnostics and surgical expertise to address complex cases like this. Raising public awareness about symptoms such as persistent facial pain and swelling, coupled with early medical intervention, can prevent severe complications.
For more information or to book an appointment at Cleveland Clinic Abu Dhabi, call 800 8 CCAD (2223) visit www.clevelandclinicabudhabi.ae or download the Cleveland Clinic Abu Dhabi Patient Portal App.
About Cleveland Clinic Abu Dhabi
Cleveland Clinic Abu Dhabi, part of the M42 group, is a multispecialty hospital located on Al Maryah Island in Abu Dhabi, UAE. As an extension of Cleveland Clinic in the U.S., it is uniquely designed to address the complex and critical care needs of the UAE and the broader region. The hospital is organized into specialized Institutes, including Heart, Vascular & Thoracic; Neurological; Cancer; Digestive Disease; Medical Subspecialties; Integrated Surgical Subspecialties; Integrated Hospital Care; and Diagnostic.
Celebrating its 10th anniversary in 2025, Cleveland Clinic Abu Dhabi is a 405-bed hospital, including 321 acute care beds, 84 critical care beds, four royal suites, and 26 operating rooms. Its state-of-the-art facilities provide patients in the region with direct access to world-class healthcare providers and Cleveland Clinic's renowned model of care. The hospital is also home to the Fatima bint Mubarak Center, a dedicated cancer center offering comprehensive diagnostics and advanced treatment across 24 clinical departments, covering a range of cancer subspecialties and programs. Committed to medical innovation, Cleveland Clinic Abu Dhabi integrates robotics across specialties, pioneers' endovascular therapy and hybrid procedures, and offers comprehensive programs in heart failure, heart transplantation, and limb salvage.
Licensed by the Department of Health – Abu Dhabi as a designated research and teaching facility, Cleveland Clinic Abu Dhabi drives medical innovation through clinical trials and advanced research to enhance patient care. It is the first hospital in the UAE accredited by both the Accreditation Council for Graduate Medical Education International (ACGMEI) and the Accreditation Council for Continuing Medical Education (ACCME), offering residency and fellowship programs, undergraduate health professional training, and Continuing Medical Education (CME).
M42 is a global, tech-enabled healthcare company based in Abu Dhabi, operating at the forefront of medical advancement.
For media inquiries, please contact:
Media Contact
Email: mfarah@webershandwick.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Zawya
5 days ago
- Zawya
M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care
Partnership will advance cancer diagnosis, inform treatment decisions, and enable real-time monitoring of disease progression in a more cost-effective and less invasive manner The launch is expected in the latter part of Q2 2025, following the completion of an initial validation study at Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.' R oss Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.


Al Etihad
5 days ago
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi


Zawya
5 days ago
- Zawya
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care.' Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region."